Our Investors in Building for the Future
Striving to increase substructure– and cell-specific targeting.
Aiming to limit or avoid on– and off-tissue toxicity.
Lowering dose requirements and costs associated with manufacturing and clinical deployment.
19% of people globally are affected by monogenic diseases, yet many go untreated due to the absence of effective therapies. Our innovative gene therapy approach aims to revolutionize treatment and bring hope to millions.
By identifying more potent and specific AAV capsid variants, Latus aims to enable low-dose gene therapies at lower costs, with improved manufacturing efficiency, and with enhancements in both efficacy and safety.
By deploying advanced computational methods and unbiased screening directly in NHP's - we're mapping the future of delivery for genetic medicines. Designed to accurately target tissues and reduce unwanted interactions, our technology aims to minimize the risks of immunogenicity and toxicity, delivering the payload exactly where it's needed.
By developing more potent AAVs, our candidates are being designed to provide improved efficacy at low doses, potentially improving costs, manufacturing efficiency and patient safety.
Latus reduces aav doses via direct routes of administration (RoA) and engineering capsids with disease-specific tropism
“I really hope we can find a way to slow down this disease. No parent wants to see their kid go through endless hospital visits, the pain of treatments, or spend their days in a hospital bed. We just want more happy, normal days at home, more laughter, and less tears—more time being a family without the constant stress of medical issues.”
“Huntngton's Disease remains a devastating, incurable genetic brain disease, for which we desperately need effective interventions. A breakthrough would be transformative for affected patients and families worldwide.”
Our team comprises industry-leading scientists, world-class clinicians and seasoned industry executives who are dedicated to revolutionizing gene therapy.
